Zentalis Pharmaceuticals, Inc.
ZNTLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. At a $216.8M market cap, Zentalis Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Market Cap
$216.8M
Beta
1.94
P/E (TTM)
—
P/E (Fwd)
-1.25
EPS (TTM)
$-1.96
EPS (Fwd)
$-1.77
ROE
-66.8%
ROA
-33.1%
Cash
$174.6M
Total Debt
$37.7M
Free CF
-$79.5M
52W Change
28.5%
Annual Financials
Cash vs Debt
Where ZNTL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ZNTL finished 38.99% below its 150-day moving average ($3.77) and 33.91% below its 200-day moving average ($3.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZNTL overbought or oversold?
At the October 20, 2026 close, ZNTL's RSI(14) was 37.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $174.6M in cash and $37.7M in debt, ZNTL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$79.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -66.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Zentalis Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Zentalis Pharmaceuticals, Inc.'s trajectory.